Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
About 20% of methicillin-susceptible Staphylococcus aureus (MSSA) isolates have a substantial inoculum effect with cefazolin, suggesting that cefazolin treatment may be associated with clinical failure for serious MSSA infections. There are no well-matched controlled studies comparing cefazolin with nafcillin for the treatment of MSSA bacteremia. A retrospective propensity-score-matched case-control study was performed from 2004 to 2009 in a tertiary care hospital where nafcillin was unavailable from August 2004 to August 2006. The cefazolin group ( n = 49) included MSSA-bacteremic patients treated with cefazolin during the period of nafcillin unavailability, while the nafcillin group ( n = 84) comprised those treated with nafcillin. Treatment failure was defined as a composite outcome of a change of antibiotics due to clinical failure, relapse, and mortality. Of 133 patients, 41 patients from each group were matched by propensity scores. There were no significant differences in baseline characteristics between the matched groups. The treatment failure rates were not significantly different at 4 or 12 weeks (10% [4/41] versus 10% [4/41] at 4 weeks [ P > 0.99] and 15% [6/41] versus 15% [6/41] at 12 weeks [ P > 0.99]). Cefazolin treatment was interrupted less frequently than nafcillin treatment due to drug adverse events (0% versus 17%; P = 0.02). Cefazolin had clinical efficacy similar to that of nafcillin and was more tolerable than nafcillin for the treatment of MSSA bacteremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Nannini, E. C., Singh, K. V., & Murray, B. E. (2003) · Clinical Infectious Diseases · doi:10.1086/379021 · Cited by 103 · cited 6×
“Among 4 identified Blas, type A Bla most efficiently hydrolyzes cefazolin (14).”
ResultInfluential
Cited by
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Li, J., Echevarria, K. L., Hughes, D. W., Cadena, J. A., Bowling, J. E., & Lewis, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02800-14 · Cited by 117
The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit560 · Cited by 90
Nannini, E. C., Singh, K. V., Arias, C. A., & Murray, B. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00856-13 · Cited by 64
Metadata
- Authors
- Lee, S., Choe, P. G., Song, K.-H., Park, S.-W., Kim, H. B., Kim, N. J., Kim, E.-C., Park, W. B., & Oh, M.-D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-11
- Volume
- 55
- Issue
- 11
- Pages
- 5122-5126
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1977027746
- Cited by
- 128
- References
- 2
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia? https://app.cochat.ai/papers/10.1128/aac.00485-11
- The paper
- Lee, S., Choe, P. G., Song, K.-H., Park, S.-W., Kim, H. B., Kim, N. J., Kim, E.-C., Park, W. B., & Oh, M.-D. (2011). Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia? Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00485-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.